On November 9, 2020, in accordance with §137h Paragraph 6 SGB V, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency within the framework of the early benefit assessment.
The evaluated product is TRICENTO, manufactured by the New Valve Technology GmbH. TRICENTO is intended for patients with severe tricuspid valve insufficiency who have corresponding symptoms, their general condition (physical performance, state of decompensation) gradually deteriorates and for which no surgical intervention is possible because of high surgical risk. The patients are in the advanced stages of the disease (NYHA III-IV).
Treatment with TRICENTO cannot be offered for the patients with anatomical peculiarities outside of the stent-graft specifications, a lung resistance >3 WU, a pressure in the right atrium >25mmHg, a pulmonary arterial blood pressure >50mmHg, and indications of an inferior pumping capacity of the right ventricle.
The full details in German can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.